The Catholic University of Korea Industry-academic Cooperation Foundation

Avago Technologies General IP (singapore) Pte. Ltd.

Curogen Technology Co., Ltd.

Electronics and Telecommunications Research Institute

Korean Broadcasting System

Bifido Co., Ltd.

Munhwa Broadcasting Corporation

Seoul Broadcasting System Co., Ltd.

Korea Educational Broadcasting System

The Catholic University of Korea Industry-academic

Sung-Hwan Park

Mi-La Cho

Min-Jung Park

Seon-Yeong Lee

Jong-Young Choi

Hyeon-Beom Seo

Seung-Hun Lee

Seung-Ki Kwok

Sung-Hee Lee

Young Kwon

Dong-Yun Shin

Chul-Woo Yang

Chang Woo Lee

Jung-Rin Woo

Joo-Yeon Jhun

Young-Mee Moon

Jin-Sil Park

Jae-yoon Ryu

Jin-Kwan Lee

Eun Kyung Kim

Jung Hyun Kim

Jin-Woo Hong

Jung-Hyun Kim

Ji-Won Kim

Won-Sik Cheong

Jooyoung Lee

Jeho Nam

Hyon-Gon Choo

Eun-Kyung Kim

Sang-Jin Kim

Eun-Jung Lee

Moon-Suk Jeon

Sangwoo Ahn

Hye-Jin Son

Geun Eog Ji

Moon-Kyun Oh

Sang-Kwon Shin

Jae-Kyung Kim

Sung-Jun Ahn

Seok-Jung Kim

Jun-Geol Ryu

Min Jung Park

Hee-Young Jun

Keunsik Lee

Bin Kwon

Byung Ha Chung

Chul Woo Yang

Kyoung-Woon Kim

Eun Ji Yang

Keun-Hyung Cho

Hui Fang

Se-Young Kim

Jooho Song

Sang-Gyou Lee

Byung-Sun Kim

Seong-Hyeok Park

Jennifer Lee

Ji-Hyeon Ju

Yunju Jeong

Su-Jin Moon

Jeong-hee Jeong

Chul- Woo Yang

The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone. Thus, the present invention may be used in the field of pharmaceutics relating to transplantation rejection or various immune disorders possibly occurring after transplantation.

Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor

The present disclosure relates to a method for inhibiting a STAT3 activity comprising administering SSu72 protein.

Method for inhibiting STAT3 activity comprising administering Ssu72

The present disclosure relates to a method of preventing rheumatoid arthritis comprising administering a polynucleotide encoding Ssu72.

Method of preventing rheumatoid arthritis comprising administering polynucleotide encoding SSU72

The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-&#x3b2; and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII. If this cell is used as a cell therapy in individuals having immune disorders, it is possible to effectively treat immune disorders.

MTOR/STAT3 signal inhibitor-treated mesenchymal stem cell having immunomodulatory activity, and cell therapy composition comprising same, for preventing or treating immune disorders

Provided is a composition containingfor alleviating, preventing or treating rheumatoid arthritis. TheATT newly isolated according to the present invention is useful as a rheumatoid arthritis medicine or a probiotic material for alleviating rheumatoid arthritis owing to potent efficacy in treating rheumatoid arthritis.

Composition containingfor alleviating, preventing or treating rheumatoid arthritis

Provided is a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present subject matter has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory T cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.

Compound having immune disease treatment effect and use thereof

A power amplifying apparatus includes a radio frequency (RF) power amplifier, a supply modulating unit, a phase shifting unit, and an envelope shaping unit. The RF power amplifier receives an input RF signal and outputs an amplified RF signal. The supply modulating unit provides the RF power amplifier with a supply voltage which varies with an original envelope of the input RF signal. The phase shifting unit receives a control signal and shifts a phase of the input RF signal to be inputted to the RF power amplifier by a shift amount which varies with the control signal. The envelope shaping unit receives the original envelope and provides the phase shifting unit with the control signal which varies with the original envelope.

Power amplifying apparatus

A power amplifier circuit for amplifying an envelope modulated Radio Frequency (RF) signal with improved linearity and efficiency includes a power amplifier, and a variable load matching circuit coupled to an output port of the power amplifier. The input impedance of the variable load matching circuit is changed such that an output power of the power amplifier is at a first output power level, or a second output power level which is higher than the first output power level.

Pulsed dynamic load modulation power amplifier circuit

Provided are an apparatus and method for controlling program conversion according to program protection information. The method for controlling conversion of a broadcasting program includes: demultiplexing a broadcasting program into broadcasting program data and program protection information; encrypting the broadcasting program data based on distribution condition of the program protection information when recordation of the broadcasting program data is requested; and recording the encrypted broadcasting program data.

Apparatus and method for controlling conversion of broadcasting program based on program protection information

Growing community of inventors

Seoul, South Korea

Sung-Hwan Park